SAN

77.36

+2.83%↑

ARGX

730.6

+2.79%↑

SHL.DE

34.97

+2.67%↑

PHIA

22.85

+3.77%↑

FRE

37.13

+1.7%↑

SAN

77.36

+2.83%↑

ARGX

730.6

+2.79%↑

SHL.DE

34.97

+2.67%↑

PHIA

22.85

+3.77%↑

FRE

37.13

+1.7%↑

SAN

77.36

+2.83%↑

ARGX

730.6

+2.79%↑

SHL.DE

34.97

+2.67%↑

PHIA

22.85

+3.77%↑

FRE

37.13

+1.7%↑

SAN

77.36

+2.83%↑

ARGX

730.6

+2.79%↑

SHL.DE

34.97

+2.67%↑

PHIA

22.85

+3.77%↑

FRE

37.13

+1.7%↑

SAN

77.36

+2.83%↑

ARGX

730.6

+2.79%↑

SHL.DE

34.97

+2.67%↑

PHIA

22.85

+3.77%↑

FRE

37.13

+1.7%↑

Home・Aandelen Lijst・Genfit

Genfit

Open

SectorGezondheidszorg

9.53 7.08

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

8.58

Max

9.74

Belangrijke statistieken
By Trading Economics
Inkomsten	-66M -76M
Verkoop	-3.6M 32M
EPS	-1.525
Winstmarge	-237.939
Werknemers	188
EBITDA	-8M -7M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+75.44% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	53M 426M
Vorige openingsprijs	2.45
Vorige sluitingsprijs	9.53

Nieuwssentiment

By Acuity

48%

52%

152 / 344 Rangschikking in Healthcare

Genfit Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 jun 2026, 21:51 UTC

Belangrijke Marktbewegers

Merlin Shares Rally After Defense Department's Design Review Wraps

4 jun 2026, 23:46 UTC

Marktinformatie

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4 jun 2026, 23:44 UTC

Marktinformatie

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4 jun 2026, 23:42 UTC

Acquisities, Fusies, Overnames

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4 jun 2026, 23:41 UTC

Acquisities, Fusies, Overnames

Energy Resources of Australia to Enter Trading Halt

4 jun 2026, 23:34 UTC

Marktinformatie

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4 jun 2026, 23:31 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

4 jun 2026, 23:31 UTC

Marktinformatie

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4 jun 2026, 23:31 UTC

Marktinformatie

Global Equities Roundup: Market Talk

4 jun 2026, 23:08 UTC

Marktinformatie

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4 jun 2026, 22:41 UTC

Marktinformatie

Australia Shares Set to Rise at the Open -- Market Talk

4 jun 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

4 jun 2026, 20:44 UTC

Acquisities, Fusies, Overnames

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4 jun 2026, 20:16 UTC

Marktinformatie

Mexican Demand Indicators Show Signs of Life -- Market Talk

4 jun 2026, 20:15 UTC

Acquisities, Fusies, Overnames

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4 jun 2026, 19:46 UTC

Marktinformatie

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4 jun 2026, 19:38 UTC

Marktinformatie

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4 jun 2026, 19:30 UTC

Marktinformatie

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4 jun 2026, 18:47 UTC

Acquisities, Fusies, Overnames

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4 jun 2026, 18:38 UTC

Winsten

Money Quote: Tech Weakness in Context -- WSJ

4 jun 2026, 18:24 UTC

Winsten

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4 jun 2026, 17:09 UTC

Marktinformatie

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4 jun 2026, 16:58 UTC

Winsten

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4 jun 2026, 16:46 UTC

Marktinformatie

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4 jun 2026, 16:38 UTC

Winsten

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4 jun 2026, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

4 jun 2026, 16:20 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

4 jun 2026, 16:13 UTC

Marktinformatie

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4 jun 2026, 16:11 UTC

Marktinformatie

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4 jun 2026, 15:56 UTC

Marktinformatie

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Peer Vergelijking

Prijswijziging

Genfit Prognose

Koersdoel

By TipRanks

75.44% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 15.001 EUR 75.44%

Hoogste 15 EUR

Laagste 15 EUR

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Genfit - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Gebaseerd op 1 analisten die aandelenratings hebben gegeven aan Genfit - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

152 / 344 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.